• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

    11/14/24 3:11:15 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPP alert in real time by email
    SC 13G/A 1 cormorant-rapp093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Rapport Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    75383L102

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  75383L102
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Cormorant Asset Management, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,940,921
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,940,921
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,940,921
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.04%
    12
    TYPE OF REPORTING PERSON
     
    IA

     
     


     

    CUSIP No.  75383L102
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Bihua Chen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,940,921
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,940,921
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,940,921
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.04%
    12
    TYPE OF REPORTING PERSON
     
    IN
     
     


     

     

    CUSIP No. 75383L102
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Rapport Therapeutics, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1325 Boylston Street, Suite 401

    Boston, MA 02215

    Item 2.(a) Names of Person Filing:

    Cormorant Asset Management, LP

    Bihua Chen

    This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 2.(b) Address of Principal Business Office:

    200 Clarendon Street, 52nd Floor

    Boston, MA 02116

     

    Item 2.(c) Citizenship:

    Cormorant Asset Management, LP - Delaware

    Bihua Chen - United States

     

    Item 2.(d) Title of Class of Securities

    Common Stock (the "Shares")

     

    Item 2.(e) CUSIP No.:

    75383L102

     

    CUSIP No.  75383L102
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 75383L102
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on November 7, 2024, that there were 36,576,457 shares of voting Common Stock of the Issuer outstanding as of November 6, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    See Item 2. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a -11.

     

     
    CUSIP No. 75383L102
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           

     

     
    CUSIP No. 75383L102
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           
    Get the next $RAPP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAPP

    DatePrice TargetRatingAnalyst
    4/8/2025Mkt Outperform
    Citizens JMP
    7/2/2024Buy
    TD Cowen
    7/2/2024$35.00Buy
    Jefferies
    7/2/2024$35.00Buy
    Stifel
    More analyst ratings

    $RAPP
    Leadership Updates

    Live Leadership Updates

    See more
    • Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

      3/11/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

      BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

      3/3/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

      Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is

      11/7/24 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    SEC Filings

    See more
    • Rapport Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

      6/2/25 4:07:20 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rapport Therapeutics Inc.

      10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)

      5/8/25 7:30:23 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

      5/8/25 7:15:09 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Rapport Therapeutics

      Citizens JMP initiated coverage of Rapport Therapeutics with a rating of Mkt Outperform

      4/8/25 9:31:03 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Rapport Therapeutics

      TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy

      7/2/24 8:03:15 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Rapport Therapeutics with a new price target

      Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00

      7/2/24 7:51:37 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Ignelzi Troy A. bought $100,988 worth of shares (10,000 units at $10.10) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      3/13/25 5:13:57 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Young Wendy B. bought $61,250 worth of shares (6,000 units at $10.21) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      3/13/25 5:00:03 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Healy James bought $1,079,575 worth of shares (44,032 units at $24.52) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      7/3/24 8:04:04 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Rapport Therapeutics Inc.

      SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/14/24 5:13:31 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

      SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/14/24 3:11:15 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rapport Therapeutics Inc.

      SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/13/24 12:26:41 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

      BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event's agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone's Comprehensive Epileps

      6/2/25 2:45:00 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

      BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) - fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time. Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL) - fireside chat on Monday, June 9, 2025, at 10:00 a.m. Eastern Time. Interested parties may access the live and archived webc

      5/27/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics to Host 2025 Investor and Analyst Day

      BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live. Rapport senior management will review the company's clinical programs, with a focus on the RAP-219 Phase 2a trial in refractory focal epilepsy. The event will also feature a fireside chat with Dr. Jacqueline A. French—a globally recognized leader in epilepsy research, profes

      5/21/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Bredt David sold $81,262 worth of shares (8,500 units at $9.56), decreasing direct ownership by 2% to 452,142 units (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      5/19/25 4:30:28 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Bredt David sold $81,310 worth of shares (8,500 units at $9.57), decreasing direct ownership by 2% to 460,642 units (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      4/16/25 5:00:04 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Sevigny Jeffrey

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      4/3/25 5:00:07 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care